Arcutis Biotherapeutics, Inc. (ARQT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 9.16 |
| Open | 9.33 |
| Bid | 8.81 x 600 |
| Ask | 8.96 x 300 |
| Day's Range | 8.85 - 9.53 |
| 52 Week Range | 1.76 - 13.17 |
| Volume | |
| Avg. Volume | 3,404,027 |
| Market Cap | 1.028B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
ZacksModerna (MRNA) Stock Outperformed Industry YTD: Here's Why
Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.
ZacksMerus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
- Zacks
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
© 2024 Yahoo. All rights reserved.